Table 1.
Clinical trials for indications of dimethyl fumarate in cardiovascular diseases *.
| Disease | Official Title | Clinical Trial (Status) | Clinicaltrial.Gov Identifier |
|---|---|---|---|
| Acute Ischemic Stroke | Combination of the immune modulator dimethyl fumarate with intra-arterial treatment in acute ischemic stroke | Phase II (Not yet recruiting) | NCT04891497 |
| Intracerebral Hemorrhage | Dimethyl fumarate for the treatment of intracerebral hemorrhage | Phase II (Not yet recruiting) | NCT04890379 |
| Acute Ischemic Stroke | Combination of the immune modulator dimethyl fumarate with alteplase in acute ischemic stroke | Phase II (Not yet recruiting) | NCT04890366 |
| Acute Ischemic Stroke | Impact of an immune modulator dimethyl fumarate on acute ischemic stroke | Phase II (Not yet recruiting) | NCT04890353 |
| Systemic Sclerosis-Associated Pulmonary Arterial Hypertension | Dimethyl fumarate in pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc-PAH): the effect of DMF on clinical disease and biomarkers of oxidative stress | Terminated | NCT02981082 |
* This list is compiled from (www.clinicaltrial.gov), accessed on 25 March 2022.